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2768therapy has been optimized and the severity of MR
subsequently reassessed.” This is precisely the point
we attempted to make, and we thank Dr. Sharma
for allowing us to clarify it. The recent American
Heart Association/American College of Cardiology
Guidelines on Valvular Heart Disease emphasize
disease staging, in which stage C is asymptomatic
severe MR and stage D is symptomatic severe MR (2).
We believe that stage C or D functional MR should
not be deﬁned by a single echocardiogram at
a given point in time, but rather by persistent
evidence of severe MR despite optimization of med-
ical therapy, cardiac resynchronization, and revas-
cularization (3). Even then, there is no convincing
evidence that surgical or percutaneous mitral
valve intervention improves survival (2,3). The eval-
uation of severe functional MR and the decision
to intervene is quite complex, with an emerging
consensus that it should be made by a multidisci-
plinary heart team (1–4).*Paul A. Grayburn, MD
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Intensity Statin Therapy
After Hospitalization for
Coronary Heart Disease
A Cause for Concern,
But a Few Words of CautionWe read with interest the paper by Rosenson et al. (1),
who performed a retrospective analysis showing that
only a “disappointing” 27% in a 5% random sample of
Medicare patients 65 to 74 years of age hospitalized
for acute myocardial infarction or revascularization
from 2007 to 2009 had been prescribed high-intensity
statins. Stricter adherence to the 2013 American Heart
Association/American College of Cardiology (AHA/
ACC) Guidelines was called for in the accompanying
editorial comment. We would like to offer some
words of caution.
Mounting evidence for harms (e.g., rhabdomyol-
ysis, diabetes, acute renal failure) (2) associated with
high-intensity statins published in the data and
treatment at our institution of 3 recent consecutive
cases of severe rhabdomyolysis (2 lethal and
1 severely debilitating, resulting in ﬂaccid quadri-
plegia) in patients treated with high-intensity statins
according to the new AHA/ACC guidelines prompted
us to review the main evidence behind those recom-
mendations, with respect to beneﬁts on “hard” end-
points such as all-cause mortality or cardiovascular
mortality.
In chronic stable coronary heart disease (CHD), 3 ma-
jor secondary prevention trials were identiﬁed: TNT
(Treat to New Targets), IDEAL (Incremental Decrease in
End Points Through Aggressive Lipid Lowering), and
SEARCH (Study of the Effectiveness of Additional
Reduction in Cholesterol and Homocysteine). From
these trials’ data, and using the latest Cochrane
methodology and focusing on outcomes that are most
relevant to patients, it was shown that high-intensity
statins had no effect on total mortality as compared
to standard dose statins (relative risk: 0.99; 95% con-
ﬁdence interval: 0.93 to 1.06). High-dose statins
increased withdrawals due to adverse effects (relative
risk: 1.45; 95% conﬁdence interval: 1.34 to 1.58;
TABLE 1 RRR and ARR for the Major Endpoints in the PROVE IT Trial
Endpoints at
the 2-Year Mark
Pravastatin 40 mg
(n ¼ 1,973)
Atorvastatin 80 mg
(n ¼ 2,003) RRR* ARR†
All-cause mortality 3.2 2.2 28 1.0
Death from CHD 1.4 1.1 30 0.3
Death/nonfatal MI 10.0 8.3 18 1.7
Values are % unless otherwise indicated. *Relative risk reduction (RRR) as published initially.
†Absolute risk reduction (ARR) not published in the original text but as calculated by us.
CHD ¼ coronary heart disease; MI ¼ myocardial infarction.
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dose statins (3).
In acute coronary syndromes, 2 major trials were
identiﬁed:
1. The A-to-Z trial compared 80 mg with 20 mg of
simvastatin in 4,497 patients with acute coronary
syndromes. There was no signiﬁcant beneﬁt in
total or cardiovascular mortality over the 2-year
duration of the study. The National Institute for
Clinical Excellence (NICE) 2014 reviewers labeled
the trial as having a high risk of bias.
2. The PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) trial investigators (4),
compared 80 mg of atorvastatin to 40 mg of pra-
vastatin in 4,162 patients in acute coronary syn-
dromes. The PROVE IT–TIMI 22 trial was reported
as strongly positive and considered to be the
cornerstone trial leading to the “sea changing” era
of intensive target-driven (“the lower, the better”)
statin therapy. It is the only one of 5 blinded trials
testing high intensity statin treatment to claim a
beneﬁt with respect to hard endpoints such as total
mortality and CHD mortality, as there were statis-
tically signiﬁcant reductions in total and CHD
mortality under the higher dose.
But a closer look at the PROVE IT–TIMI 22 trial
shows negligible absolute beneﬁts.
For the “hardest” endpoints (Table 1), such as
death from all causes, at the 24-month mark, the
absolute risk reduction was a mere 1% (3.2% on pra-
vastatin 40 mg vs. 2.2% on atorvastatin 80 mg);
for deaths from CHD, the absolute risk reduction
was smaller, at 0.3% (about 6 patients), the differ-
ence between 1.4% (or about 28 patients) on pravas-
tatin 40 mg versus 1.1% (or about 22 patients) on
atorvastatin 80 mg. In the published paper, when
expressed as relative risk reductions, the beneﬁts
look much more impressive: reductions of 28% for
death and 30% for CHD death. Moreover, we do not
know what to think about the erratum (4) published 2
years later, wherein the authors admitted to multiple
inaccuracies (typo errors quite unlikely) in the
reporting of the numbers of patients at risk at every
time mark (6, 12, 18, 24, and 30 months) and in both
groups.
The authors have neither redone the calculations
of the Kaplan-Meier curves nor retracted the paper.
Had they redone the calculations, would the small
differences of 1% in absolute risk reduction in overall
mortality—and the 0.3% absolute risk reduction in
CHD mortality—in the high-intensity group have
remained unaffected?In conclusion, worthwhile beneﬁts have not been
clearly demonstrated with high-intensity statins, as
compared to lower doses, with respect to “hard” end-
points such as total mortality or CV mortality.
It is doubtful that the small, if any, beneﬁts of high-
potency statins on soft and less patient-relevant
outcomes, outcomes that are highly susceptible to
biases (5), would outweigh the combined risks of
acute kidney injury, rhabdomyolysis, diabetes, and
severe muscular failure, not to mention dozens of
other adverse reactions (2). Because the beneﬁts do
not bear scrutiny of the evidence, the harms caused
may be substantial and the societal costs incurred by
abiding to the new AHA/ACC guidelines would be
enormous. We therefore suggest that until proven
otherwise, a cause for concern is not with “under-
utilization of high-intensity statins” but rather may
be with their “overutilization.”*Paul V. Nguyen, MD
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